Overview
Segolene Martin is the CEO and cofounder of Kantify, a company she cofounded in April 2016 and which is based in Brussels. She is also vice-chair of lifetech.brussels, where she has sat on the advisory board since February 2021, a working group member on innovation and commercialisation at the Global Partnership on Artificial Intelligence, and a member of the European Commission / Digital SME Focus Group on AI.
Her earlier roles include chief marketing officer at Meetsies, and two positions at CEN and CENELEC, where she was programme manager for innovation from 2011 to 2013 and then unit manager for technical policy until 2015. From December 2005 she was a policy officer responsible for research, innovation and business at the EU Representation Office of Regions Bretagne/Pays de la Loire/Poitou Charentes, and from 2009 she also coordinated the Automotive Crisis Intergroup at the Committee of the Regions. She worked at Euregio Maas Rijn in 2004 and at ERRIN in 2005.
She served on the boards of BeCode.org and Cluster software.brussels, and was Women in AI ambassador for Belgium from 2018 to 2022. She holds a master's degree in European public affairs from Sciences Po Strasbourg and an MBA from The Open University.
Career history
Media & appearances
- AI4Belgium & Data Science CommunityYouTubeDISUMMIT AI-Awards: Kantify announcement by Segolene MartinSegolene Martin announces that she is the CEO of Kantify, a machine learning consultancy, and that she has been nominated for an AI award. She invites viewers to vote for her and Kantify and mentions looking forward to meeting people at an event on June 26th.
- Leyton BeneluxYouTubeFull IV - Ségolène Martin (CEO Kantify)Ségolène Martin discusses how Kantify, her artificial intelligence-focused startup, uses AI technology to accelerate drug discovery for diseases like cancer and rare diseases that currently lack known treatments. She explains the company's three-pillar philosophy combining economic value with societal impact (providing hope to patients waiting for therapies) and environmental impact (testing far fewer molecules through AI screening rather than hundreds of thousands of chemical tests).
- Le VifYouTubeSégolène Martin - CEO de KantifySegolene Martin discusses her excitement about being a CEO in her thirties, noting that at this age she combines accumulated experience and professional networks with energy and time ahead of her. She identifies common traits among entrepreneurs and business creators as the desire to make a difference, ambition, and perseverance, and expresses her intention to continue working in technology and entrepreneurship for decades to come rather than retire.
In the news
- I’m speaking at FTI Brussels! As part of the Business track Human & Health, I’ll be joining the session "Low Tech, High Touch: Person-Centered Care in Practice", curated by Sofie Bekaert. I'm looking forward to to catching up with Nathalie Lambrechts (We Are/VITO) and meeting Inge Tency (Odisee), Véronique Peters, Annick Dermine (Huis voor Gezondheid), and Alexandra Coppieters (Gibbis). All-star cast on stage the same day - Erik Janssen, Koen Kas, Segolene Martin, Gilles Jourquin, Vincent Keunen, and even more familiar
- Sapian is not only novel but also validated multiple times in wet lab for its capacity to find novel chemistry even for the toughest cases, aka the undruggable.
- Sapian just managed to yield **splendid** results in 4 drug discovery projects - and September has not even started. Feeling humbled to work with such a team.
- To quote Mark Murcko, ""Structure is beauty, but not always truth". What if alternative, non structure-based drug discovery approaches could step in, when structural approaches fail? Discover what is one of the multiple differences of our AI platform Sapian, as explained by Diana Sarkees. ✅ Sapian, Kantify's AI platform, has had multiple in vitro /vivo validations with several labs in Europe and US. ✅ Including for previously unliganded targets. ✅ Check our pipeline page, see for yourself, and 📧 Get in touch.
- A very inspiring lady 🌍 https://lnkd.in/eN9DWhxR
- Do you know the fairy tale "Le Petit Poucet" (Little Thumb)? In the story, the smallest brother manages to steal the ogre's seven-league boots: magic boots that let you cross seven leagues in a single step. These magic boots save him and his family. When confronted to a disease where research is struggling to move fast, who doesn't hope for something that makes science progress much faster, like magic boots would? To a growing number of scientists and patients, AI in drug discovery has this kind of "magic boot" potential. Let's be
- One part of Jack Scannell's interview in Decoding Bio caught my eye, as it resonates very much with what we observe at Kantify. No further comment needed. Nb: 2 years ago Kantify released 3 articles looking at known molecules and their AI-predicted targets. https://lnkd.in/ePwEM2Yr - This work (and similar ones) is currently being used by some partners to understand (and confirm through experimental validation, obviously) why these well-known molecules sometimes reveal new and misunderstood therapeutic effects.
- Almost 100 years ago, in October 1927, an extraordinary conference was held in our home city, Brussels. The world's leading physicists gathered for the fifth Solvay Conference. The photograph from that meeting - Einstein, Bohr, Heisenberg, Schrödinger, Planck, Curie, Dirac, and others - has become shorthand for a defining moment in the development of modern physics. The Solvay Conferences themselves were born from Brussels' connection to modern industrial chemistry. Ernest Solvay, the Belgian industrialist who funded them, had
Related profiles
This page shows public professional information only, each fact cited. Is this you? send a correction, or ask for removal within 24 hours, no questions asked.